LYMPHOVASCULAR SPACE INVASION IN PATIENTS WITH EARLY STAGE ENDOMETRIOID ADENOCARCINOMA OF THE ENDOMETRIUM: THE ROLE OF ADJUVANT THERAPY

Objectives: Aim of this study was to evaluate the effect of adjuvant therapy on the recurrence and on the overall survival in patients with early stage endometrioid adenocarcinoma of endometrium and lymphovascular space invasion (LVSI) treated with primary surgery. Methods: 48 patients with endometrioid adenocarcinoma of endometrium and LVSI were evaluated in this retrospective study. The Log-Rank test was used for statistical analyses and the Kaplan-Meyer method was used for time-to-event analysis. Results: 14 (29%) received radiotherapy as adjuvant therapy, whereas 34 (71%) did not received any adjuvant therapy. Between the patients who underwent adjuvant therapy, 4 (28%) developed a recurrence, the median time to recurrence was 26 months (8-53) and the median survival after recurrence was 56 months (29-120). 12(50%) patients who had not received any therapy relapsed, the median time to recurrence was 12 months (4-38) and the median survival after recurrence was 30 months (14-93). The analysis demonstrated that adjuvant therapy is not associated neither to a decreased in the occurrence of relapse (p=0,2), neither to an increase in survival (p=0,1). Conclusion: The administration of adjuvant radiotherapy in patients with recurrent endometrioid adenocarcinoma of early stage endometrial cancer and LVSI does not affect neither the occurrence of relapse, neither the overall survival.